Abbvie Inc

NYSE: ABBV
$182.75
+$1.61 (+0.9%)
Real Time Data Delayed 15 Min.

ABBV Articles

The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
With interest rates once again dropping as the geopolitical worries ratchet up, investors are concerned about owning good stocks and receiving dependable dividends. One place that looks very good now...
The March 31 short interest data have been compared with the previous figures, and short interest decreased in most of these selected pharmaceutical stocks.
The March 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks was mixed.
The February 28 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The top analyst upgrades, downgrades and initiations seen on Friday include AbbVie, KLA-Tencor, Marathon Oil and Verifone.
The top analyst upgrades, downgrades and initiations seen on Tuesday include AbbVie, Frontier Communications, Hyatt Hotels and Weatherford International.
Judging by this report, short sellers are making a tremendous bet against Trump’s plan to reform the health care sector.
A new Jefferies research report features its third big change for 2017. Plus four top dividend-paying stocks that long like great buys now.
It has yet to be seen how much headway Trump can actually make with heath care reforms, but so far the reaction has been quite positive.
Jefferies has made a third big change for 2017 by adding Marathon Petroleum to the Franchise Picks list. Plus, three more top dividend-paying stocks from the list.
AbbVie reported mixed fourth-quarter financial results and offered guidance before the markets opened on Friday.
The January 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mostly down.
The health care sector has some of its biggest players reporting later this week, with one pharma giant’s report already out of the way.
A new Jefferies research report makes the case that while market parameters are indeed expensive, there still are cheap stocks to buy that have a large enough market cap to provide some safety.